December 1, 2016
Otsuka Pharmaceutical Co., Ltd.
FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of Abilify Maintena® (aripiprazole) For The Treatment Of Bipolar I Disorder
- Application seeks to expand ABILIFY MAINTENA label to include maintenance treatment for bipolar I disorder
- If the label expansion is approved, ABILIFY MAINTENA would offer prescribers a once-monthly long-acting injectable treatment option in the maintenance treatment of bipolar I disorder in adults
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck announced the U.S. Food and Drug Administration (FDA) has determined that the supplemental New Drug Application (sNDA) for the expanded labeling of ABILIFY MAINTENA® for the maintenance treatment of bipolar I disorder in adult patients is sufficiently complete to permit a substantive review and is considered filed. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of July 28, 2017, to complete its review.
Information in this news release was current as of the original release date.